Literature DB >> 31175415

Amide proton transfer imaging might predict survival and IDH mutation status in high-grade glioma.

Bio Joo1, Kyunghwa Han1, Sung Soo Ahn2, Yoon Seong Choi1, Jong Hee Chang3, Seok-Gu Kang3, Se Hoon Kim4, Jinyuan Zhou5, Seung-Koo Lee1.   

Abstract

OBJECTIVES: To assess the utility of amide proton transfer (APT) imaging as an imaging biomarker to predict prognosis and molecular marker status in high-grade glioma (HGG, WHO grade III/IV).
METHODS: We included 71 patients with pathologically diagnosed HGG who underwent preoperative MRI with APT imaging. Overall survival (OS) and progression-free survival (PFS) according to APT signal, clinical factors, MGMT methylation status, and IDH mutation status were analyzed. Multivariate Cox regression models with and without APT signal data were constructed. Model performance was compared using the integrated AUC (iAUC). Associations between APT signals and molecular markers were assessed using the Mann-Whitney test.
RESULTS: High APT signal was a significant predictor for poor OS (HR = 3.21, 95% CI = 1.62-6.34) and PFS (HR = 2.22, 95% CI = 1.33-3.72) on univariate analysis. On multivariate analysis, high APT signals were an independent predictor of poor OS and PFS when clinical factors alone (OS: HR = 2.89; PFS: HR = 2.13), or in combination with molecular markers (OS: HR = 2.85; PFS: HR = 2.00), were included as covariates. The incremental prognostic value of APT signals was significant for OS and PFS. IDH-wild type was significantly associated with high APT signals (p = 0.001) when compared to IDH-mutant; however, there was no difference based on MGMT methylation status (p = 0.208).
CONCLUSION: High APT signal was a significant predictor of poor prognosis in HGG. APT data showed significant incremental prognostic value over clinical prognostic factors and molecular markers and may also predict IDH mutation status. KEY POINTS: • Amide proton transfer (APT) imaging is a promising prognostic marker of high-grade glioma. • APT signals were significantly higher in IDH-wild type compared to IDH-mutant high-grade glioma. • APT imaging may be valuable for preoperative screening and treatment guidance.

Entities:  

Keywords:  Glioma; Isocitrate dehydrogenase; Magnetic resonance imaging; Prognosis

Mesh:

Substances:

Year:  2019        PMID: 31175415      PMCID: PMC6859837          DOI: 10.1007/s00330-019-06203-x

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  13 in total

Review 1.  Clinical Imaging for Diagnostic Challenges in the Management of Gliomas: A Review.

Authors:  Alipi V Bonm; Reed Ritterbusch; Patrick Throckmorton; Jerome J Graber
Journal:  J Neuroimaging       Date:  2020-01-10       Impact factor: 2.486

2.  Prediction of H3K27M-mutant brainstem glioma by amide proton transfer-weighted imaging and its derived radiomics.

Authors:  Zhizheng Zhuo; Liying Qu; Peng Zhang; Liwei Zhang; Yaou Liu; Yunyun Duan; Dan Cheng; Xiaolu Xu; Ting Sun; Jinli Ding; Cong Xie; Xing Liu; Sven Haller; Frederik Barkhof
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-06-16       Impact factor: 9.236

3.  3D Amide Proton Transfer-Weighted Imaging for Grading Glioma and Correlating IDH Mutation Status: Added Value to 3D Pseudocontinuous Arterial Spin Labelling Perfusion.

Authors:  Huimin Hou; Weibo Chen; Yanzhao Diao; Yuhan Wang; Li Zhang; Liming Wang; Min Xu; Jinchao Yu; Tao Song; Yu Liu; Zhenguo Yuan
Journal:  Mol Imaging Biol       Date:  2022-08-12       Impact factor: 3.484

4.  Vessel Size Imaging is Associated with IDH Mutation and Patient Survival in Diffuse Lower-Grade Glioma.

Authors:  Houyi Kang; Peng Chen; Hong Guo; Letian Zhang; Yong Tan; Hualiang Xiao; Ao Yang; Jingqin Fang; Weiguo Zhang
Journal:  Cancer Manag Res       Date:  2020-10-08       Impact factor: 3.989

5.  CEST MRI provides amide/amine surrogate biomarkers for treatment-naïve glioma sub-typing.

Authors:  Laura Mancini; Stefano Casagranda; Guillaume Gautier; Philippe Peter; Bruno Lopez; Lewis Thorne; Andrew McEvoy; Anna Miserocchi; George Samandouras; Neil Kitchen; Sebastian Brandner; Enrico De Vita; Francisco Torrealdea; Marilena Rega; Benjamin Schmitt; Patrick Liebig; Eser Sanverdi; Xavier Golay; Sotirios Bisdas
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-14       Impact factor: 10.057

6.  Anatomic and Molecular MR Image Synthesis Using Confidence Guided CNNs.

Authors:  Pengfei Guo; Puyang Wang; Rajeev Yasarla; Jinyuan Zhou; Vishal M Patel; Shanshan Jiang
Journal:  IEEE Trans Med Imaging       Date:  2021-09-30       Impact factor: 11.037

7.  Structural plasticity of the bilateral hippocampus in glioma patients.

Authors:  Taoyang Yuan; Jianyou Ying; Zhentao Zuo; Songbai Gui; Zhixian Gao; Guilin Li; Yazhuo Zhang; Chuzhong Li
Journal:  Aging (Albany NY)       Date:  2020-06-05       Impact factor: 5.682

8.  Amide proton transfer weighted (APTw) imaging based radiomics allows for the differentiation of gliomas from metastases.

Authors:  Elisabeth Sartoretti; Thomas Sartoretti; Michael Wyss; Carolin Reischauer; Luuk van Smoorenburg; Christoph A Binkert; Sabine Sartoretti-Schefer; Manoj Mannil
Journal:  Sci Rep       Date:  2021-03-09       Impact factor: 4.379

9.  Correlation between amide proton transfer-related signal intensity and diffusion and perfusion magnetic resonance imaging parameters in high-grade glioma.

Authors:  Masanori Nakajo; Manisha Bohara; Kiyohisa Kamimura; Nayuta Higa; Takashi Yoshiura
Journal:  Sci Rep       Date:  2021-05-27       Impact factor: 4.379

10.  Predicting cancer malignancy and proliferation in glioma patients: intra-subject inter-metabolite correlation analyses using MRI and MRSI contrast scans.

Authors:  Changliang Su; Shihui Li; Xiaowei Chen; Chengxia Liu; Mehran Shaghaghi; Jingjing Jiang; Shun Zhang; Yuanyuan Qin; Kejia Cai
Journal:  Quant Imaging Med Surg       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.